Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A method for estimating the probability of adverse drug reactions
19818.4k citationsC. A. Naranjo, U. Busto et al.Clinical Pharmacology & Therapeuticsprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by D J Greenblatt
Since
Specialization
Citations
This map shows the geographic impact of D J Greenblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D J Greenblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D J Greenblatt more than expected).
This network shows the impact of papers produced by D J Greenblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D J Greenblatt. The network helps show where D J Greenblatt may publish in the future.
Co-authorship network of co-authors of D J Greenblatt
This figure shows the co-authorship network connecting the top 25 collaborators of D J Greenblatt.
A scholar is included among the top collaborators of D J Greenblatt based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with D J Greenblatt. D J Greenblatt is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kaplan, Gary B., et al.. (1992). Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy.. PubMed. 6(3). 145–53.40 indexed citations
Greenblatt, D J, Ann Locniskar, J. M. Scavone, et al.. (1986). Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam.. PubMed. 65(2). 176–80.27 indexed citations
11.
Shader, Richard I., D J Greenblatt, & Louis Lasagna. (1986). Illness Care???A Finite System?. Journal of Clinical Psychopharmacology. 6(5). 257–257.4 indexed citations
12.
Naranjo, C. A., U. Busto, Edward M. Sellers, et al.. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics. 30(2). 239–245.8382 indexed citations breakdown →
13.
Greenblatt, D J, et al.. (1978). Clinical pharmacokinetics of lorazepam: a review.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 39(10 Pt 2). 16–23.64 indexed citations
14.
Greenblatt, D J, Richard I. Shader, Käte Franke, & J S Harmatz. (1978). Pharmacokinetics of chlordiazepoxide and metabolites following single and multiple oral doses.. PubMed. 16(10). 486–93.8 indexed citations
Greenblatt, D J & Richard I. Shader. (1970). Adverse effects of LSD: a current perspective.. PubMed. 34(12). 895–902.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.